Inhibitex to Present at the 2011 Canaccord Genuity Growth Conference on Tuesday, August 9th

ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Canaccord Genuity Growth Conference on Tuesday, August 9, 2011 at 3:30 p.m. EDT. The conference is being held at The Intercontinental Hotel in Boston, Massachusetts. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.

About Inhibitex

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline currently includes two Phase 2 development programs; INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections and FV-100, a nucleoside analogue in development for the treatment of shingles-associated pain. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.



CONTACT:

Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, 646-378-2922
[email protected]

KEYWORDS:   United States  North America  Georgia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.